Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program

Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX) announces a conference call on December 5, 2022, at 8:00 a.m. ET to discuss updated clinical data from its ongoing Phase 1 trial of NKX019, a CD19-directed CAR NK cell therapy. NKX019 is designed to treat relapsed/refractory B cell malignancies and is being assessed for safety and anti-tumor activity as both monotherapy and combination therapy. The call will provide vital insights into the therapy's progress, and accompanying slides will be accessible on Nkarta's website.

Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate.

Conference Call and Webcast
To access the conference call, please register through this link:
https://nkarta-nkx019-clinical-update-conference-call.open-exchange.net/registration

Accompanying slides will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.

About NKX019
NKX019, a wholly owned program of Nkarta, is an investigational healthy donor-derived CAR NK cell therapy targeting CD19. NKX019 is being investigated in an ongoing Phase 1 single-arm, open label, multi-center, international clinical trial that is designed to assess the safety and anti-tumor activity of NKX019 as a multi-dose, multi-cycle monotherapy and combination therapy in patients with relapsed/refractory B cell malignancies.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com

FAQ

What is NKX019 and its purpose?

NKX019 is a CD19-directed CAR NK cell therapy being developed by Nkarta to treat relapsed/refractory B cell malignancies.

When is the Nkarta conference call scheduled?

The conference call is scheduled for December 5, 2022, at 8:00 a.m. ET.

How is NKX019 being tested?

NKX019 is currently undergoing a Phase 1, single-arm, open-label, multi-center clinical trial to evaluate its safety and effectiveness.

Where can I find the clinical data presented by Nkarta?

Updated clinical data and slides from the conference call will be available on Nkarta's Investors website.

What type of therapy is NKX019?

NKX019 is an investigational therapy derived from healthy donors, focusing on CAR NK cell technology.